Tango Therapeutics posted a Q4 2025 net loss of USD 38.7 million, or USD 0.29 per share, and a FY 2025 net loss of USD 101.6 million, or USD 0.87 per share. R&D expenses were USD 32.1 million in Q4 and USD 132.2 million in FY, while G&A expenses were USD 9.8 million in Q4 and USD 41.5 million in FY. Collaboration revenue was no revenue in Q4 (as remaining deferred revenue under the Gilead collaboration was recognized in Q3 2025 following truncation of the agreement) and USD 62.4 million in FY 2025. Tango ended 2025 with USD 343.1 million in cash, cash equivalents and marketable securities, and said this is expected to fund operations into 2028. On the business side, Tango said it expects to initiate a pivotal study of vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer in 2026, and anticipates initial Phase 1/2 safety and efficacy data in 2026 from its vopimetostat combinations with Revolution Medicines’ RAS$(ON)$ inhibitors daraxonrasib and zoldonrasib. The company also announced a clinical trial collaboration and supply agreement with Erasca to evaluate vopimetostat with ERAS-0015, a pan-RAS molecular glue. Corporate updates included the appointment of Philippe Serrano as Chief Regulatory Officer and a CEO transition in January 2026, with Malte Peters succeeding founder Barbara Weber, who moved to Executive Chair through 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050700PRIMZONEFULLFEED9666235) on March 05, 2026, and is solely responsible for the information contained therein.